APO RESEARCH · REPORT
Generic Injectables
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
Product & engineering
Understand the product.
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
Selected research
Industry Growth & Trends
Global Generic Injectables Industry Growth and Trends Forecast to 2032
Market perspective
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
According to APO Research, the global Generic Injectables market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Generic Injectables market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Generic Injectables market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Generic Injectables market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Generic Injectables.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Generic Injectables market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Generic Injectables Market by Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Generic Injectables Segment by Type
Small Molecule
Large Molecule
Generic Injectables Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Generic Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Generic Injectables companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Large Molecule
Applications
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular Diseases
Companies covered
- Hospira (Pfizer Inc.)
- Fresenius Kabi
- Sandoz (Novartis)
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd
- Grifols
- Nichi-Iko Group (Sagent)
- Teva Pharmaceutical
- Auromedics
- Sanofi
- Gland Pharma
- Endo International PLC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Generic Injectables Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Generic Injectables Market Size by Region (2021-2032)
- 1.4.1 Global Generic Injectables Market Size by Region (2021-2026)
- 1.4.2 Global Generic Injectables Market Size by Region (2027-2032)
- 1.5 Key Regions Generic Injectables Market Size (2021-2032)
- 1.5.1 North America Generic Injectables Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Generic Injectables Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Generic Injectables Market Size Growth Rate (2021-2032)
- 1.5.4 South America Generic Injectables Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Generic Injectables Market Size Growth Rate (2021-2032)
2 Generic Injectables Market by Type
- 2.1 Type Introduction
- 2.1.1 Small Molecule
- 2.1.2 Large Molecule
- 2.2 Global Generic Injectables Market Size by Type
- 2.2.1 Global Generic Injectables Market Size Overview by Type (2021-2032)
- 2.2.2 Global Generic Injectables Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Generic Injectables Market Size Forecasted by Type (2027-2032)
- 2.3 Global Generic Injectables Market Size by Regions
- 2.3.1 North America Generic Injectables Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Generic Injectables Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Generic Injectables Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Generic Injectables Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Generic Injectables Market Size Breakdown by Type (2021-2026)
3 Generic Injectables Market by Application
- 3.1 Type Introduction
- 3.1.1 Oncology
- 3.1.2 Anesthesia
- 3.1.3 Anti-Infectives
- 3.1.4 Parenteral Nutrition
- 3.1.5 Cardiovascular Diseases
- 3.2 Global Generic Injectables Market Size by Application
- 3.2.1 Global Generic Injectables Market Size Overview by Application (2021-2032)
- 3.2.2 Global Generic Injectables Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Generic Injectables Market Size Forecasted by Application (2027-2032)
- 3.3 Global Generic Injectables Market Size by Regions
- 3.3.1 North America Generic Injectables Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Generic Injectables Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Generic Injectables Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Generic Injectables Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Generic Injectables Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Generic Injectables Industry Trends
- 4.2 Generic Injectables Industry Drivers
- 4.3 Generic Injectables Industry Opportunities and Challenges
- 4.4 Generic Injectables Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Generic Injectables Revenue (2021-2026)
- 5.2 Global Generic Injectables Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Generic Injectables Key Company Headquarters & Area Served
- 5.4 Global Generic Injectables Company, Product Type & Application
- 5.5 Global Generic Injectables Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Generic Injectables Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Generic Injectables Players Market Share by Revenue in 2025
- 5.6.3 2025 Generic Injectables Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Hospira (Pfizer Inc.)
- 6.1.1 Hospira (Pfizer Inc.) Company Information
- 6.1.2 Hospira (Pfizer Inc.) Business Overview
- 6.1.3 Hospira (Pfizer Inc.) Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
- 6.1.5 Hospira (Pfizer Inc.) Recent Developments
- 6.2 Fresenius Kabi
- 6.2.1 Fresenius Kabi Company Information
- 6.2.2 Fresenius Kabi Business Overview
- 6.2.3 Fresenius Kabi Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Fresenius Kabi Generic Injectables Product Portfolio
- 6.2.5 Fresenius Kabi Recent Developments
- 6.3 Sandoz (Novartis)
- 6.3.1 Sandoz (Novartis) Company Information
- 6.3.2 Sandoz (Novartis) Business Overview
- 6.3.3 Sandoz (Novartis) Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sandoz (Novartis) Generic Injectables Product Portfolio
- 6.3.5 Sandoz (Novartis) Recent Developments
- 6.4 Hikma Pharmaceuticals PLC
- 6.4.1 Hikma Pharmaceuticals PLC Company Information
- 6.4.2 Hikma Pharmaceuticals PLC Business Overview
- 6.4.3 Hikma Pharmaceuticals PLC Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
- 6.4.5 Hikma Pharmaceuticals PLC Recent Developments
- 6.5 Dr. Reddy’s Laboratories Ltd
- 6.5.1 Dr. Reddy’s Laboratories Ltd Company Information
- 6.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
- 6.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
- 6.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
- 6.6 Grifols
- 6.6.1 Grifols Company Information
- 6.6.2 Grifols Business Overview
- 6.6.3 Grifols Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Grifols Generic Injectables Product Portfolio
- 6.6.5 Grifols Recent Developments
- 6.7 Nichi-Iko Group (Sagent)
- 6.7.1 Nichi-Iko Group (Sagent) Company Information
- 6.7.2 Nichi-Iko Group (Sagent) Business Overview
- 6.7.3 Nichi-Iko Group (Sagent) Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
- 6.7.5 Nichi-Iko Group (Sagent) Recent Developments
- 6.8 Teva Pharmaceutical
- 6.8.1 Teva Pharmaceutical Company Information
- 6.8.2 Teva Pharmaceutical Business Overview
- 6.8.3 Teva Pharmaceutical Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Teva Pharmaceutical Generic Injectables Product Portfolio
- 6.8.5 Teva Pharmaceutical Recent Developments
- 6.9 Auromedics
- 6.9.1 Auromedics Company Information
- 6.9.2 Auromedics Business Overview
- 6.9.3 Auromedics Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Auromedics Generic Injectables Product Portfolio
- 6.9.5 Auromedics Recent Developments
- 6.10 Sanofi
- 6.10.1 Sanofi Company Information
- 6.10.2 Sanofi Business Overview
- 6.10.3 Sanofi Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Sanofi Generic Injectables Product Portfolio
- 6.10.5 Sanofi Recent Developments
- 6.11 Gland Pharma
- 6.11.1 Gland Pharma Company Information
- 6.11.2 Gland Pharma Business Overview
- 6.11.3 Gland Pharma Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Gland Pharma Generic Injectables Product Portfolio
- 6.11.5 Gland Pharma Recent Developments
- 6.12 Endo International PLC
- 6.12.1 Endo International PLC Company Information
- 6.12.2 Endo International PLC Business Overview
- 6.12.3 Endo International PLC Generic Injectables Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Endo International PLC Generic Injectables Product Portfolio
- 6.12.5 Endo International PLC Recent Developments
7 North America
- 7.1 North America Generic Injectables Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Generic Injectables Market Size by Country (2021-2026)
- 7.3 North America Generic Injectables Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Generic Injectables Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Generic Injectables Market Size by Country (2021-2026)
- 8.3 Europe Generic Injectables Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Generic Injectables Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Generic Injectables Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Generic Injectables Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Generic Injectables Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Generic Injectables Market Size by Country (2021-2026)
- 10.3 South America Generic Injectables Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Generic Injectables Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Generic Injectables Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Generic Injectables Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst